Amino acids and peptides. XXV. Preparation of fibronectin-related peptide poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. 1995

K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Japan.

Hybrids of fibronectin-related peptides [Arg-Gly-Asp (RGD), Arg-Gly-Asp-Ser (RGDS)] and poly(ethylene glycol) (PEG) were prepared and their inhibitory effects on experimental metastasis in mice were examined. The inhibitory effect of RGD was markedly potentiated by hybrid formation with poly(ethylene glycol) #6000. As to inhibitory effect, RGD was more potent than RGDS and RGD PEG hybrids were superior to RGDS PEG hybrids. Hybrid formation with PEG #6000 was more effective than that with PEG #4000.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
June 1996, Biological & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
December 1997, Biochemical and biophysical research communications,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
November 1997, Chemical & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
February 1998, Chemical & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
April 2001, Chemical & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
September 1994, Chemical & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
December 1996, Biological & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
July 1998, Biochemical and biophysical research communications,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
June 1994, Biological & pharmaceutical bulletin,
K Kawasaki, and M Namikawa, and Y Yamashiro, and Y Iwai, and T Hama, and Y Tsutsumi, and S Yamamoto, and S Nakagawa, and T Mayumi
November 1993, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!